MedPath

Synergia Medical Secures €9 Million in Series B Funding for Epilepsy Treatment Innovation

Synergia Medical, a preclinical medical device company, has successfully raised €9 million in Series B funding. This financial boost will support the company's preparation for First-In-Human clinical trials of its NAO.VNS device, aimed at treating drug-resistant epilepsy, and the submission of an Investigational Device Exemption to the FDA in 2023.

Belgium, September 12, 2022 – Synergia Medical, a preclinical medical device company specializing in the development of NAO.VNS (Vagus Nerve Stimulation), has announced the successful completion of a €9 million Series B funding round. This significant financial achievement enables the company to prepare for First-In-Human clinical trials planned for 2023 and the submission of an Investigational Device Exemption (IDE) to the FDA in the USA. The IDE allows the investigational device to be used in clinical studies to collect safety and efficacy data.
The funding round saw participation from a mix of historical private shareholders, Newton Biocapital, public investors (SFPI, SRIW Life Sciences, Investsud), the Walloon region, and was joined by the institutional investor TheClubDeal, which specializes in the life sciences, technology, and Smart Living sectors.
Attila Borbath, CEO & Co-founder of Synergia Medical, expressed his gratitude towards the investors for their confidence and support, highlighting the importance of this funding in advancing their clinical trials and regulatory milestones. Sophie Baratte, Chairman of the Board of Directors, emphasized the company's commitment to improving the lives of epilepsy patients through innovative Vagus Nerve Stimulation treatment.
Jean-Marc Legrand, CEO of TheClubDeal, praised Synergia Medical for its breakthrough project and the capable team behind it, noting the company's solid patents as a key factor in their investment decision.
Since its inception in 2016, Synergia Medical has raised over €26 million. The company employs 25 staff members, focusing on pre-clinical studies, R&D, and expertise in quality and regulatory affairs. It is supported by a business-oriented Board of Directors with extensive experience in the health sector and a Scientific Advisory Board comprising world-renowned experts in neural stimulation and epilepsy.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Be Bio Secures $92 Million to Advance B Cell Medicines for Hemophilia B and Hypophosphatasia

- Be Bio has closed a $92 million Series C financing round to advance its B cell medicine (BCM) programs for hemophilia B and hypophosphatasia.
- The funding will support clinical proof-of-concept for BE-101 in a Phase 1/2 trial for hemophilia B and advance BE-102 for hypophosphatasia to the clinic.

Synergia Medical's NAO.VNS Device Shows Promising Results in First-in-Human Study for Drug-Resistant Epilepsy

- Synergia Medical's NAO.VNS device met the primary safety endpoint in its first-in-human clinical study, with no serious adverse events reported over three months.
- The study demonstrated robust device performance with no device failures reported, showcasing the potential of the next-generation neuromodulation platform.

Nkarta's NKX019 Cell Therapy Trial Opens Enrollment for ANCA-Associated Vasculitis

- Nkarta has initiated enrollment for the Ntrust-2 clinical trial to evaluate NKX019 cell therapy in patients with ANCA-associated vasculitis (AAV) and other autoimmune disorders.
- The Ntrust-2 trial will assess the safety and efficacy of NKX019 in promoting long-term disease remission in up to 12 participants with AAV, systemic sclerosis, or idiopathic inflammatory myopathy.

SynOx Therapeutics Raises $92 Million and Doses First Patients in Phase 3 TGCT Trial

- SynOx Therapeutics secured an additional investment in its Series B financing, bringing the total to $92 million to support the Phase 3 TANGENT trial.
- The TANGENT trial is evaluating emactuzumab, a CSF-1R inhibiting monoclonal antibody, for the treatment of Tenosynovial Giant Cell Tumour (TGCT).

SynOx Therapeutics Raises $92 Million and Doses First Patients in Phase 3 TGCT Trial

- SynOx Therapeutics secured $92 million in Series B funding to advance the Phase 3 TANGENT trial of emactuzumab for Tenosynovial Giant Cell Tumour (TGCT).
- The TANGENT trial is a global, randomized, double-blind, placebo-controlled study evaluating emactuzumab's efficacy and safety in TGCT patients.

Agomab Therapeutics Secures $89 Million to Advance Fibrotic Disease Treatments

- Agomab Therapeutics has raised $89 million in Series D funding to support clinical trials for its fibrotic disease treatments, including AGMB-129.
- AGMB-129, an oral small molecule inhibitor of ALK5 (TGFβ1R), is currently in a Phase IIa trial (STENOVA) for fibrostenosing Crohn’s disease, with interim results expected in early 2025.

Synergy Spine Solutions Completes Enrollment in Synergy Disc 2-Level IDE Clinical Trial

- Synergy Spine Solutions has completed patient enrollment in its U.S. 2-Level IDE clinical trial for the Synergy Disc.
- The trial evaluates the safety and effectiveness of the Synergy Disc compared to anterior cervical discectomy and fusion (ACDF) for degenerative disc disease.

Synergia Medical Implants First Patients with Novel Neurostimulator for Epilepsy

- Synergia Medical has implanted its NAO.VNS device in first-in-human study participants with drug-resistant epilepsy, testing a novel neurostimulation technology.
- The AURORA trial, conducted across sites in Belgium and Germany, will evaluate the safety and efficacy of Synergia's vagus nerve stimulation therapy.

Synergia Medical's NAO.VNS System Successfully Implanted in First-in-Human Epilepsy Study

- Synergia Medical successfully implanted its NAO.VNS system in two patients with drug-resistant epilepsy as part of the AURORA study.
- The first-in-human implantations occurred at Cliniques Universitaires Saint-Luc and UZ Gent, with both patients recovering fully and starting stimulation therapy.

ByHeart Secures $90M Series B Funding After Successful Infant Formula Clinical Trial

- ByHeart secured $90 million in Series B funding to launch its infant formula and advance its pipeline of mom and baby products.
- The company's clinical trial with 311 babies met all endpoints, a key step for FDA submission and market entry.

Reference News

[1]
SYNERGIA MEDICAL SUCCESSFULLY RAISES SERIES ...
synergia-medical.com · Sep 12, 2022

Synergia Medical completed a €9 million Series B funding, enabling First-In-Human trials for its NAO.VNS device targetin...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy